Evidence method
Level · gp.fundamentals.debt_to_revenue
1663.08% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
BBIO · Sep 30, 2025
BridgeBio Pharma, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001743881-25-000012General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.39% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-90.78% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
20.32% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
94.56% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-120.30% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
93.52% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
29.22% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History5 statesHistory building
Period transition
What moved in the state?
- Previous
- 0.54%
- Current
- 0.39%
- Delta
- -0.15%
- Previous
- -72.97%
- Current
- -90.78%
- Delta
- -17.81%
- Previous
- 16.53%
- Current
- 20.32%
- Delta
- 3.79%
- Previous
- 96.70%
- Current
- 94.56%
- Delta
- -2.13%
- Previous
- -121.45%
- Current
- -120.30%
- Delta
- 1.15%
- Previous
- 100.60%
- Current
- 93.52%
- Delta
- -7.09%
- Previous
- 33.77%
- Current
- 29.22%
- Delta
- -4.55%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · BBIO Fundamental State →Has State · BridgeBio Pharma, Inc. →Transitioned To · BBIO Fundamental State →Transitioned To · BBIO CAPEX_INTENSITY_DECREASED →Transitioned To · BBIO CASH_GENERATION_DECREASED →Transitioned To · BBIO INVENTORY_PRESSURE_INCREASED →Transitioned To · BBIO MARGIN_DECREASED →Transitioned To · BBIO PROFITABILITY_INCREASED →Transitioned To · BBIO R_AND_D_INTENSITY_DECREASED →Transitioned To · BBIO SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.